Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Trial Profile

Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs APX 005M (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Apr 2017 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
    • 19 Apr 2017 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top